What do oncologists need to know about biosimilar products?

  title={What do oncologists need to know about biosimilar products?},
  author={Linda K. S. Leung and Kevin Mok and Calvin Liu and Stephen L. Chan},
  booktitle={Chinese journal of cancer},
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments. Approval of a biosimilar product relies on the demonstration of "comparability" or "no clinically meaningful differences" as compared to its reference biologic product. Biosimilar products for erythropoietin, granulocyte colony-stimulating factor, trastuzumab… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 24 references

announces AcellBia is first mAb biosimilar approved by the Ministry of Health of the Russian Federation

  • PR Newswire. 2014. http:// www.prnewswire.com…
  • 2016
Highly Influential
3 Excerpts

Key Results of International Randomized Open-Label Clinical Study of BCD-020 (rituximab biosimilar candidate) in Patients with B-Cell NonHodgkin’s Lymphoma

  • K Kaplanov, A Zaritskiy, S Alexeev, E Volodicheva, A Loginov, R Orlova
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…